Abaxis (ABAX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend
October 24, 2017 4:01 PM EDTUNION CITY, Calif., Oct. 24, 2017 /PRNewswire/ -- Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the second fiscal quarter ended September 30, 2017.
Second quarter results include:
Revenues of $58.9 million, up 1% over last year's comparable quarter. Veterinary market revenues of $48.5 million, up 1% over last year's comparable quarter. International revenues of $11.9 million, up 3% over last year's comparable quarter. Revenues from sales of consumables, which include reagent discs, hematology... More